GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $9.36 Consensus Price Target from Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $9.36.

GDRX has been the topic of a number of recent research reports. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price objective on shares of GoodRx in a research note on Friday, August 16th. Raymond James raised GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective on the stock in a research note on Friday, August 9th. UBS Group reduced their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research report on Friday, August 9th. Finally, Citigroup decreased their price target on GoodRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 9th.

GoodRx Stock Performance

NASDAQ GDRX opened at $6.90 on Tuesday. The stock’s fifty day moving average is $7.44 and its two-hundred day moving average is $7.58. The firm has a market capitalization of $2.62 billion, a P/E ratio of -53.08, a price-to-earnings-growth ratio of 4.44 and a beta of 1.37. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.32. GoodRx has a fifty-two week low of $4.14 and a fifty-two week high of $9.26.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The company had revenue of $200.60 million for the quarter, compared to analyst estimates of $200.47 million. GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The business’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the firm posted $0.02 EPS. On average, research analysts anticipate that GoodRx will post 0.14 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.17% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On GoodRx

Several hedge funds have recently bought and sold shares of the company. Cornercap Investment Counsel Inc. lifted its stake in GoodRx by 1.7% during the 2nd quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock worth $587,000 after acquiring an additional 1,266 shares in the last quarter. California State Teachers Retirement System raised its position in GoodRx by 5.1% in the 1st quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock valued at $503,000 after purchasing an additional 3,444 shares in the last quarter. US Bancorp DE raised its position in GoodRx by 3.7% in the 1st quarter. US Bancorp DE now owns 109,818 shares of the company’s stock valued at $780,000 after purchasing an additional 3,877 shares in the last quarter. Beacon Capital Management LLC acquired a new stake in GoodRx in the 1st quarter valued at about $28,000. Finally, Plato Investment Management Ltd acquired a new stake in GoodRx in the 2nd quarter valued at about $43,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.